Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clopidogrel injunction retained

Executive Summary

A preliminary injunction halting sales of generic Plavix by Apotex has been upheld by Washington, D.C. Federal Appeals Court, Sanofi-Aventis and Bristol-Myers Squibb announce Dec. 8. The ruling affirms the Aug. 31 decision by the U.S. District Court for the Southern District of New York granting Sanofi/Bristol's motion for a preliminary injunction enjoining Apotex from infringing Sanofi's patent by selling generic clopidogrel (1"The Pink Sheet" Sept. 4, 2006, p. 3). Sanofi/Bristol filed the motion for preliminary injunction Aug. 15 in response to Apotex' Aug. 8 "at risk" launch. Apotex said it is considering further review of the lower court decision. The trial on the underlying patent infringement dispute is scheduled to begin Jan. 22...

You may also be interested in...

Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi

The impact of the launch of a generic version of Plavix - the second best selling drug in the world - will continue to weigh on Sanofi-Aventis and Bristol-Myers Squibb at least through the remainder of the year and possibly beyond despite a ruling in their favor barring Apotex' sale of generic clopidogrel

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts